Trump secures drug pricing deals with 9 pharma firms, bringing total to 26
- Trump administration secures drug pricing deals with 9 new pharma firms, bringing total to 26 companies
- These 26 firms represent 90% of the US pharmaceutical market, according to President Trump
- New signatories commit to $19.6 billion in US manufacturing investment and Medicaid discounts
- White House estimates potential savings of $529 billion for the economy over the next decade

*this image is generated using AI for illustrative purposes only.
President Donald Trump secured new drug pricing agreements with nine pharmaceutical companies, expanding the administration's total deals to 26 firms. These entities now represent 90% of the US pharmaceutical market, according to the President.
New agreements and commitments
The nine new signatories include Alcon Inc., Astellas Pharma, BeOne Medicines Ltd., BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals Industries Ltd., and UCB. The deals require these companies to offer discounts on outpatient drugs across all state Medicaid programs, aiming to align US prices with international markets.
Beyond pricing, the companies committed to collectively investing at least $19.6 billion in US manufacturing in the near term. Astellas, Sun Pharma, Teva, and UCB also agreed to donate active pharmaceutical ingredients for key medicines to the federal government’s strategic reserve.
| Metric | Detail |
|---|---|
| Total companies in deals | 26 |
| Market share represented | 90% |
| New manufacturing investment | $19.6 billion |
| Key new signatories | Alcon, Astellas, Teva, Sun Pharma, UCB |
Market concentration and policy context
These agreements build on 17 previous deals struck over the past year with firms including Pfizer Inc., Eli Lilly And Co, and Novo Nordisk A/S. The policy aims to reduce exposure to tariffs by shifting manufacturing to the US while lowering costs through direct-to-consumer platforms like TrumpRx.
White House economists estimated in May that these pricing deals could lead to savings of $529 billion for the economy over the next decade. Additionally, federal and state governments could save $64.3 billion on Medicaid due to the "most favored nation" policy on drug prices.
What the Numbers Show
The consolidation of 90% of the market into just 26 agreements highlights the high degree of concentration in the US pharmaceutical sector. While the $19.6 billion manufacturing commitment signals a shift in supply chain geography, the requirement for Medicaid discounts directly pressures revenue streams, as noted by Novo Nordisk’s expectation that higher prescription volumes will take time to offset price declines.
How will the mandated Medicaid discounts impact the R&D budgets and future pipeline innovation of the 26 signatory pharmaceutical companies?
What are the potential supply chain risks or delays associated with shifting $19.6 billion in manufacturing capacity to the US in the near term?
Could the 'most favored nation' pricing model trigger retaliatory trade measures or regulatory hurdles for US pharma exports in international markets?

























